Zobrazeno 1 - 5
of 5
pro vyhledávání: '"556"'
Autor:
Gabriele Matschiner, Corinna Schlosser, Sven Berger, Marlon Hinner, Ulrich Moebius, Christine Rothe, Alexander Wiedenmann, Andrea Allersdorfer, Rachida-Siham Bel Aiba, Shane Olwill
Publikováno v:
Cancer Research. 76:556-556
Background. CD137 (4-1BB) is a key costimulatory immunoreceptor and a member of the TNF-receptor (TNFR) superfamily. While multiple lines of evidence show that CD137 is a highly promising therapeutic target in cancer, current mAb-based approaches are
Autor:
Chelsea Jin, Maher Albitar, Vladislav Chizhevsky, Virginia Burns, Sucha Sudarsanam, Cory Batenchuk
Publikováno v:
Cancer Research. 77:4015-4015
Background: Higher levels of PD-L1 expression at the surface of tumor cells have been associated with increased response to anti-PD-1 therapies (Santabarbara G et al. Ann Transl Med. 2016;4:215; Borghaei H et al. N Engl J Med. 2015;373:1627-1639; Bra
Autor:
Niall Lennon, Elana Anastasio, Todd R. Golub, K Larken, Dewey Kim, EP Winer, Elizabeth S. Frank, M Krevalin, Eric S. Lander, Corrie A. Painter
Publikováno v:
Cancer Research. 77:P1-05
Background: The Metastatic Breast Cancer Project is a nationwide research initiative that directly engages patients through social media and advocacy groups and seeks to empower them to share their samples and clinical information to accelerate resea
Autor:
Christian U. Blank, Michal Lotem, Clemens Krepler, Teresa M. Petrella, Matteo S. Carlino, Caroline Robert, Georgina V. Long, Paul Lorigan, Antoni Ribas, James Larkin, Omid Hamid, Laurent Mortier, Jean-Jacques Grob, James R. Anderson, Catriona M. McNeil, Scott J. Diede, Bart Neyns, Ana Arance, Jacob Schachter, Adil Daud
Publikováno v:
Cancer Research. 79:CT188-CT188
Introduction: Pembro significantly improved OS vs ipi in advanced melanoma in the KEYNOTE-006 study (NCT01866319). We present outcomes from the 5-year follow-up of this study−the longest to date in a randomized phase 3 trial of pembro in advanced c
Autor:
Rami I. Aqeilan, Maria Sundvall, Marius Sudol, Johan Lundin, Anna Korhonen, Heikki Joensuu, Jorma Isola, Eugenio Gaudio, Valentina Donati, Carlo M. Croce, Klaus Elenius, Milena S. Nicoloso
Publikováno v:
Cancer Research. 67:9330-9336
WWOX, WW domain-containing oxidoreductase, is a tumor suppressor that is altered in many human cancers, including breast cancer. Wwox interacts with the ErbB4 receptor, reduces nuclear translocation of the cleaved intracellular domain of ErbB4, and i